乐铂单药治疗肺癌的临床研究  

A Pilot Study ot Lobaplatin as a Single Agent in the Treatment of Lung Cancer

作　　者：姜文奇[1] 林桐榆[1] 徐瑞华[1] 管忠震[1] 

机构地区：[1]中山医科大学肿瘤医院,广州510060

出　　处：《浙江肿瘤》1998年第4期211-212,共2页

摘　　要：（目的）评价乐铂单药治疗恶性肿瘤的疗效，同时观察其毒副反应。（方法）并入选肺癌病人105例，包括非小细胞肺．癌（NSCLC）48例、小细胞肺癌（SCLC）57例。应用单药乐铂50mg／m2静脉滴注，每3周1个疗程，平均治疗2个疗程。（结果）非小细胞肺癌患者，4例PR，有效率8．3％，小细胞肺癌患者，1例CR，23例PR，有效率为421％。白细胞下降Ⅰ～Ⅱ级为37.1％，Ⅲ级为8．7％；血小板下降Ⅰ～Ⅱ组为33．9％，Ⅲ级为11．9％；血色素下降Ⅰ～Ⅱ级为12．9％，Ⅲ级为41％；胃肠道毒性Ⅰ～Ⅱ级为43．4％，Ⅲ级为4．6％。（结论）乐铂对小细胞肺癌的疗效较好。主要剂量限制性毒性为骨髓毒性，特别是血小板减少。乐铂直接的肾毒性不明显。[Purpose] To study the efficasy and adverse effects of using Iobaplatin to treat small cell and non-small cell lungcancer. [Methods] One hundred and five patients with histologically proven SCLC and NSCLC received single agent therapy bylobaplatin 50 mg/m2 iv drip, repeat every 3 weeks and average 2 cycles were given. [Results] Out of 48 NSCLC, 4 PR, RR 8. 3%were observed and out of 57 SCLC, 1 CR, 23 PR, RR 42. 1 % were observed. The main adverse effects (Ⅲ /N grade) wereleukopenia(8. 7 % ), thrombocytopenia (11. 9%), erythrocytopenia(4. 1 % ), vomiting(4. 6 % ). [Conclusioll] Lobaplatin is effectivein treating SCLC. The main dosage litheting toxicity of lobaplatin is myelotoxicity, especially thrombocytopenia. No obviotisnephrotoxicity was observed.

关 键 词：乐铂 肺肿瘤 药物疗法 毒副反应 治疗 

分 类 号：R734.205[医药卫生—肿瘤]